PSYENCE BIOMEDICAL LTD. (PBM) Form 6-K — Jun 5, 2026
Psyence Biomedical Ltd. filed a Form 6-K to disclose the Board's approval of an amendment to its 2023 Equity Incentive Plan. The amendment was executed specifically to correct a typographical error in Section 4(b) of the original plan document. The filing includes the full text of the First Amended and Restated Plan as Exhibit 10.1.
Key figures
- Plan share limit pre consolidation
- 8150126
- Plan share limit post consolidation
- 13635
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.